Cargando…

Management and investigation of neonatal encephalopathy: 2017 update

This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A com...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinello, Kathryn, Hart, Anthony R, Yap, Sufin, Mitra, Subhabrata, Robertson, Nicola J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537522/
https://www.ncbi.nlm.nih.gov/pubmed/28389438
http://dx.doi.org/10.1136/archdischild-2015-309639
_version_ 1783254197482815488
author Martinello, Kathryn
Hart, Anthony R
Yap, Sufin
Mitra, Subhabrata
Robertson, Nicola J
author_facet Martinello, Kathryn
Hart, Anthony R
Yap, Sufin
Mitra, Subhabrata
Robertson, Nicola J
author_sort Martinello, Kathryn
collection PubMed
description This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A combination of careful history, examination and the judicious use of investigations can help determine the cause. Over the last 7 years, infants with moderate to severe HIE have benefited from the introduction of routine therapeutic hypothermia; the number needed to treat for an additional beneficial outcome is 7 (95% CI 5 to 10). More recent research has focused on optimal resuscitation practices for babies with cardiorespiratory depression, such as delayed cord clamping after establishment of ventilation and resuscitation in air. Around a quarter of infants with asystole at 10 min after birth who are subsequently cooled have normal outcomes, suggesting that individualised decision making on stopping resuscitation is needed, based on access to intensive treatment unit and early cooling. The full benefit of cooling appears to have been exploited in our current treatment protocols of 72 hours at 33.5°C; deeper and longer cooling showed adverse outcome. The challenge over the next 5–10 years will be to assess which adjunct therapies are safe and optimise hypothermic brain protection in phase I and phase II trials. Optimal care may require tailoring treatments according to gender, genetic risk, injury severity and inflammatory status.
format Online
Article
Text
id pubmed-5537522
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55375222017-08-03 Management and investigation of neonatal encephalopathy: 2017 update Martinello, Kathryn Hart, Anthony R Yap, Sufin Mitra, Subhabrata Robertson, Nicola J Arch Dis Child Fetal Neonatal Ed Review This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A combination of careful history, examination and the judicious use of investigations can help determine the cause. Over the last 7 years, infants with moderate to severe HIE have benefited from the introduction of routine therapeutic hypothermia; the number needed to treat for an additional beneficial outcome is 7 (95% CI 5 to 10). More recent research has focused on optimal resuscitation practices for babies with cardiorespiratory depression, such as delayed cord clamping after establishment of ventilation and resuscitation in air. Around a quarter of infants with asystole at 10 min after birth who are subsequently cooled have normal outcomes, suggesting that individualised decision making on stopping resuscitation is needed, based on access to intensive treatment unit and early cooling. The full benefit of cooling appears to have been exploited in our current treatment protocols of 72 hours at 33.5°C; deeper and longer cooling showed adverse outcome. The challenge over the next 5–10 years will be to assess which adjunct therapies are safe and optimise hypothermic brain protection in phase I and phase II trials. Optimal care may require tailoring treatments according to gender, genetic risk, injury severity and inflammatory status. BMJ Publishing Group 2017-07 2017-04-06 /pmc/articles/PMC5537522/ /pubmed/28389438 http://dx.doi.org/10.1136/archdischild-2015-309639 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Review
Martinello, Kathryn
Hart, Anthony R
Yap, Sufin
Mitra, Subhabrata
Robertson, Nicola J
Management and investigation of neonatal encephalopathy: 2017 update
title Management and investigation of neonatal encephalopathy: 2017 update
title_full Management and investigation of neonatal encephalopathy: 2017 update
title_fullStr Management and investigation of neonatal encephalopathy: 2017 update
title_full_unstemmed Management and investigation of neonatal encephalopathy: 2017 update
title_short Management and investigation of neonatal encephalopathy: 2017 update
title_sort management and investigation of neonatal encephalopathy: 2017 update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537522/
https://www.ncbi.nlm.nih.gov/pubmed/28389438
http://dx.doi.org/10.1136/archdischild-2015-309639
work_keys_str_mv AT martinellokathryn managementandinvestigationofneonatalencephalopathy2017update
AT hartanthonyr managementandinvestigationofneonatalencephalopathy2017update
AT yapsufin managementandinvestigationofneonatalencephalopathy2017update
AT mitrasubhabrata managementandinvestigationofneonatalencephalopathy2017update
AT robertsonnicolaj managementandinvestigationofneonatalencephalopathy2017update